The vaptans ante portas: A status report

Nephrology Dialysis Transplantation

Volumn 24, Issue 5, 2009, Pages 1371-1373

  Gross, Peter ^a   Marczewski, Tadeusz ^b   Herbrig, Kay ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

Cardiac failure; Cerebral salt wasting; Hyponatraemia; Liver cirrhosis; Vasopressin antagonists

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONIVAPTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TOLVAPTAN; VASOPRESSIN; VASOPRESSIN ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR;

BLEEDING; CEREBRAL SALT WASTING; DRUG APPROVAL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; EDEMA; EMERGENCY TREATMENT; HEART FAILURE; HUMAN; HYPONATREMIA; LIVER CIRRHOSIS; NOTE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; THIRST; TREATMENT FAILURE; XEROSTOMIA;

BENZAZEPINES; HEART FAILURE; HUMANS; HYPONATREMIA; RECEPTORS, VASOPRESSIN; TREATMENT OUTCOME; VASOPRESSINS;

EID: 65249118223     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp034     Document Type: Note

References (13)

1. Schrier RW, Gross P et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist for hyponatremia. N Engl J Med 2006; 355: 2099-2112
2. Soupart A, Gross P et al. Successful long-term treatment of hy-ponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vaso-pressin V2-receptor antagonist. Clin J Am Soc Nephrol 2006; 1: 1154- 1160
3. Shea AM, Hammill BGet al.Medical costsofabnormal serumsodium levels. J Am Soc Nephrol 2008; 19: 764-770
4. Decaux G. Is asymptomatic hyponatremia really asymptomatic? Am J Med 2006; 119: S79-S82
5. Gutierrez OM, Lin HY. Refractory hyponatremia. Kidney Int 2007; 71: 79-82
6. Feldman BJ, Rosenthal SM et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005; 352: 1884-1890
7. Decaux G, Vandergheynst et al. Nephrogenic syndrome of inappropriate antidiuresis in adults: high phenotypic variability in men and women from a large pedigree. J Am Soc Nephrol 2007; 18: 606- 612
8. -/- mice. J Am Soc Nephrol 2007; 18: 1672-1678
9. Ahrabi AK, Terryn S et al. PKD1 haploinsufficiency causes a syndrome of inappropriate antidiuresis in mice. J Am Soc Nephrol 2007; 18: 1740-1753
10. Lehrich RW, Greenberg A. When is it appropriate to use vasopressin receptor antagonists? J Am Soc Nephrol 2008; 19: 1054-1058
11. Konstam MA, Gheorghiade M et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure. JAMA 2007; 297: 1319-1331
12. Inoue T, Ohnishi A et al. Therapeutic and diagnostic potential of a vasopressin-2 antagonist for impaired water handling in cirrhosis.Clin Pharmacol Ther 1998; 63: 561-570
13. + storage in the skin. Am J Physiol Heart Circ Physiol 2004; 287: H203-H208